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ABSTRACT 
Objective: The preliminary goal was to develop and validate 1st order derivative spectroscopic method for quantitative analysis of Pamabrom 
(PAMA) which is a xanthine diuretic and ibuprofen (IBU) which is a non-steroidal anti-inflammatory agent from its synthetic mixture. 
Methods: Analytical method was developed on Shimadzu double beam spectrophotometer equipped with UV probe 2.42 as software using 
methanol as solvent. Quantification of PAMA was carried out at zero cross over point of IBU that is 291 nm and for IBU, it was achieved at 278 nm 
which is zero cross over point of PAMA. Method was validated according to ICH Q2 R1 guidelines. 
Results: Method showed a linear response in the range of 2-12 µg/ml of PAMA and 20-120 µg/ml of IBU. Method was found to be accurate with recovery 
between 99.7–100.9 % for PAMA and 100.3–100.7 % for IBU. The method was found to be accurate and precise for quantitative analysis of PAMA and IBU. 
Conclusion: The developed method was successfully validated as per ICH Q2 R1 guidelines and was successfully applied for quantitative analysis of 
a synthetic mixture of PAMA and IBU. 
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Pamabrom (PAMA) belongs to the class of xanthene diuretics, which 
basically contains purine moiety and is approved by US FDA for 
treatment of menstruation bloating, premenstrual dysphoric disorders, 
while ibuprofen (IBU) is non-steroidal anti-inflammatory (NSAID’s) drug 
that is propionic acid derivative which is approved by Indian 
pharmacopoeia (IP), United states pharmacopoeia (USP) and Japanese 
pharmacopoeia (JP) for management of mild-to-moderate pain 
associated with dysmenorrhea and arthritis [1-7]. 40–90 % of women of 
childbearing age complained of primary dysmenorrhea, which is 
characterized in cyclic pelvic pain during the menstrual period, vomit 
and headache. NSAIDs were administered to patients because 
prostaglandins and leukotriene were reported as major factors for 
dysmenorrhea. Among the all NSAID’s, IBU has shown better tolerability 
which forms the basis of combining PAMA and IBU for treatment of pain 
associated with renal calculi and dysmenorrhea. PAMA and IBU are 
officially quantified by HPLC [8]. Several analytical methods are available 
which can determine IBU and PAMA individually or in combination with 
another drug [9-26]. Literature review revealed one complex RP-HPLC 
method for quantitative analysis of PAMA and IBU.  
Among different analytical methods, UV spectrophotometric method 
is perhaps the most quickest and robust method and no UV 
spectrophotometric method has been reported for estimation of IBU 
and PAMA in synthetic mixture. More specifically derivative 
spectroscopy has the advantage to be more specific in comparison to 
other multicomponent UV spectrophotometric methods. 
So by considering the above facts, it was decided to develop and 
validate 1st order derivative spectrophotometric method for 
quantitative analysis of IBU and PAMA, as it has less complexity and 
offers a better economy.  
MATERIALS AND METHODS 
Materials 
PAMA was obtained as gratis sample (99.95% pure) for research 
purpose from Amoli organics, Vadodara while IBU was obtained as 
gratis sample from OSAKA pharmaceuticals, Sakrda, Baroda. 
Methanol (LR grade) was purchase from SD fines. 
Instrument and experimental conditions 
Spectrophotometric analysis was performed on Shimadzu UV-1800 
double beam spectrophotometer having a path length of 1 cm 
matched pair of quartz cell. Obtained spectra of PAMA and IBU were 
derivatized to 1st order using UV probe 2.42 as software at delta ʎ of 
10 nm. 
Preparation of master stock solution 
For the method development purpose, 10 mg of PAMA was weighed 
and diluted to 10 ml (1000 µg/ml) and was further diluted to give 
final concentration of 100 µg/ml. In a similar way, 50 mg of IBU was 
weighed and diluted to 50 ml (1000 µg/ml) and was further diluted 
to give the final concentration of 200 µg/ml. 
Selection of analytical wavelength 
The working standards of PAMA (2-12 μg/ml) and IBU (20-120 
μg/ml) were prepared in 10 ml volumetric flask using methanol as a 
solvent. They were scanned in the UV range of 200–400 nm and D ° 
spectra is recorded by UV spectrophotometer. All the D ° spectra of 
PAMA and IBU were transformed into D1 spectra with the help of UV 
probe 2.42 software. For confirmation of D1 spectra of PAMA and 
IBU, D ° and D1 spectra of the same were overlapped.  
Preparation of solutions for analytical method validation 
Preparation of solution for linearity and range 
To check the linearity of the method, PAMA was prepared in the 
concentration range of 2-16 µg/ml and IBU was prepared in the 
range of 20-160 µg/ml from master stock solution in 10 ml 
volumetric flask. When D1 Absorbance was plotted against 
concentration, non-linearity was observed above 12 µg/ml for 
PAMA and above 120 µg/ml for IBU so final range for validation was 
selected at mixture containing 2-12 µg/ml for PAMA and 20-120 
µg/ml for IBU. All prepared solution was scanned between 200-400 
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nm and all spectra were derivatized to 1st order. D1 absorbance was 
obtained at selected wavelength and mean D1 absorbance was 
plotted against concentration. 
Intermediate precision (Repeatability) 
To adjudge the repeatability of the analytical method, the solution of 
linearity studies were analyzed for five-time with same conditions. 
Mean D1 absorbance was recorded at all concentration for PAMA 
and IBU and were observed for relative standard deviation. 
Method precision 
Method precision was determined by performing intraday and 
interday precision. The mixture that represents overall range (2+20, 
8+80 and 12+120µg/ml) were analyzed on the same day at different 
time interval for intraday precision. The mixture that represents 
overall range (2+20, 8+80 and 12+120 µg/ml) were analyzed on 
different days for interday precision. 
Accuracy study 
Accuracy of the analytical method was adjudged by spiking of 
placebo with standard solution. The mixture containing 100 mg of 
directly compressible lactose, 2 mg of talc and 2 mg of magnesium 
stearate was selected as placebo and was spiked at 50, 100 and 
150% of target concentration (8+80 µg/ml) (table 1). Each spiked 
concentration was analyzed for three times and mean % recovery 
was observed at each spiked level. 
 
Table 1: Preparation of solutions for accuracy study 
Level of 
spiking 
Quantity of placebo 
(mg) 
The volume of stock solution 
(ml) 




  PAMA IBU 
Unspiked 104 0 10 - - 
50 % 104 0.4 9.6 4 40 
100 % 104 0.8 9.2 8 80 
150 % 104 1.2 8.8 12 120 
A stock solution was prepared by weighing 5 mg PAMA and 50 mg IBU and was dissolved in 50 ml methanol (100 µg/ml for PAMA and 1000 µg/ml 
for IBU respectively) 
 
Solvent stability 
Solvent stability was determined by scanning the same solution 
prepared in selected solvent (methanol) at 3 different time interval 
that is at 0 hour, 6 h and 24 h. The mixture of 12+120 µg/ml solution 
of PAMA and IBU in methanol were scanned at the selected time 
interval and characteristics of spectra were compared (λmax). 
Assay 
As the proposed synthetic mixture is having dose of 20 mg of PAMA 
and 200 mg of IBU, 20 mg of PAMA and 200 mg of IBU was mixed 
with selected placebo, and diluted appropriately to give a mixture 
containing 8 µg/ml of PAMA and 80 µg/ml of IBU. This mixture was 
scanned between 200-400 nm and was derivatized to 1st order. D1 
absorbance was measured at selected wavelengths and was 
transformed to concentration with help of linear regression 
equation. This mixture was analyzed for three times and the mean % 
assay was drawn. 
RESULTS AND DISCUSSION 
Selection of analytical wavelength 
Three different ZCP at 278 nm, 316 nm and 245 nm was observed in 
overlain D1 spectra of PAMA (fig. 1). Three different ZCP at 250 nm, 261 
nm and 291 nm were observed in overlain D1 spectra of IBU (fig. 2). For 
determination of analytical wavelength D1 spectra of PAMA and IBU 
were overlapped (fig. 3). While recording D1 absorbance of PAMA at ZCP 
of IBU, nonlinearity was observed at 250 and 261 nm while at 291, the 
linear response was observed with concentration (fig. 4). In similar way 
at ZCP of PAMA, linearity was observed only at 278 nm for IBU (fig. 5). So 
291 nm and 278 nm was selected as analytical wavelength for 
quantitative determination of PAMA and IBU respectively. 
  
 
Fig. 1: Zero cross over point of PAMA 
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Fig. 2: Zero cross over point of IBU 
 
 
Fig. 3: Overlain D1 spectra of IBU and PAMA 
 
 
Fig. 4: Determination of PAMA at ZCP of IBU at 291 nm (12 µg/ml) 
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Fig. 5: Determination of IBU at ZCP of PAMA at 278 nm (120 µg/ml) 
 
Analytical method validation 
Linearity and range 
When D1 Absorbance was plotted against concentration, non-
linearity was observed above 12 µg/ml for PAMA and above 120 
µg/ml for IBU, so final range for validation was selected at mixture 
containing 2-12 µg/ml for PAMA and 20-120 µg/ml for IBU (fig. 6). 
When the calibration curve was plotted for given concentration 
range (fig. 7 and 8), value of linear regression coefficient was found 
to be 0.99898 for PAMA and 0.99876 for IBU. Regression equation 
was found to be y = 0.00361 X–0.00051 for PAMA and y = 0.00008 
X–0.00011 for IBU. Linearity data for both drugs is shown in table 2. 
 
 
Fig. 6: D1 Spectra of a standard mixture of IBU (20-120µg/ml) and PAMA (2-12 µg/ml) for linearity stud 
 
Table 2: Linearity data for PAMA and IBU 
S. No. For PAMA For IBU 
Conc. (µg/ml) mean±SD RSD Conc. (µg/ml) mean±SD RSD 
1 2 -0.00716±0.00011 1.592 20 -0.00159±0.000013 0.815 
2 4 -0.01516±0.00011 0.752 40 -0.00317±0.000042 1.329 
3 6 -0.02276±0.00011 0.500 60 -0.00478±0.000045 0.947 
4 8 -0.02944±0.00011 0.387 80 -0.00616±0.00011 1.850 
5 10 -0.03654±0.00011 0.312 100 -0.00756±0.00011 1.508 
6 12 -0.04358±0.00008 0.191 120 -0.00936±0.00011 1.218 
(n= 5 determinations) 
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Fig. 7: Calibration curve of PAMA at 291 nm 
 
 
Fig. 8: Calibration curve of IBU at 278 nm 
 
Repeatability 
When all mixture were analyzed at all concentration, calculated 
relative standard deviation at each level was found to be less than 2 
so that method was found to be repeatable over the range of 2-12 
µg/ml for PAMA and 20-120 µg/ml for IBU. Repeatability data are 
shown in table 3 and 4 for PAMA and IBU, respectively. 
Method precision 
For determining interday and intraday precision, RSD was 
monitored at selected concentration level, which was found to be 
less than 2 so the method was found to be precise for estimation of 
PAMA and IBU. Data for intermediate precision are given in table 5 
and 6 for PAMA and INU respectively. 
 
Table 3: Repeatability data for PAMA at 291 nm 
Conc. (µg/ml) 2 4 6 8 10 12 
 
D1 Absorbance 
-0.0072 -0.0152 -0.0228 -0.0294 -0.0365 -0.0436 
-0.0071 -0.0153 -0.0227 -0.0295 -0.0368 -0.0435 
-0.007 -0.015 -0.0228 -0.0296 -0.0364 -0.0437 
-0.0072 -0.0151 -0.0226 -0.0293 -0.0365 -0.0436 
-0.0073 -0.0152 -0.0229 -0.0294 -0.0367 -0.0435 
Mean -0.00716 -0.01516 -0.02276 -0.02944 -0.03654 -0.04358 
SD 0.000114 0.000114 0.000114 0.000114 0.000114 0.00008 
R. SD 1.592 0.752 0.500 0.387 0.312 0.191 
(n= 5 determinations) 
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Table 4: Repeatability data for IBU at 278 nm 
Conc.(µg/ml) 20 40 60 80 100 120 
 
D1 Absorbance 
-0.00161 -0.0032 -0.0048 -0.0062 -0.0076 -0.0094 
-0.00159 -0.00319 -0.0047 -0.0061 -0.0077 -0.0095 
-0.00161 -0.0031 -0.0048 -0.0063 -0.0075 -0.0093 
-0.00158 -0.00318 -0.00481 -0.0062 -0.0076 -0.0092 
-0.0016 -0.0032 -0.00479 -0.006 -0.0074 -0.0094 
Mean -0.00159 -0.00317 -0.00478 -0.00616 -0.00756 -0.00936 
SD 0.00001 0.00004 0.00004 0.00011 0.00011 0.00011 
R. SD 0.815 1.329 0.947 1.850 1.508 1.218 
(n= 5 determinations) 
 
Table 5: Intraday and interday precision for PAMA 
Conc. (µg/ml) Intraday (mean+SD) RSD Inter-day (mean+SD) RSD 
2 -0.007192+0.000013 0.18 -0.007228+0.000019 0.26 
8 -0.0294+0.00015 0.53 -0.02942+0.00019 0.65 
12 -0.04362+0.00025 0.59 -0.0446+0.00035 0.79 
(n=3 determinations) 
 
Table 6: Intraday and interday precision for IBU 
Conc. (µg/ml) Intraday (mean+SD) RSD Inter-day (mean+SD) RSD 
20 -0.00162+0.000019 1.19 -0.001736+0.000021 1.19 
80 -0.0062+0.000042 0.67 -0.0066+0.000026 0.38 
120 -0.00932+0.000113 1.20 -0.00966+0.000036 0.36 
(n=3 determinations) 
 
Table 7: Accuracy data of PAMA and IBU by derivative spectroscopy method 
Level of spiking Total placebo (mg) Amount of std. drug added (µg/ml) Amount of drug recovered (µg/ml) % recovery 
PAMA IBU PAMA IBU PAMA IBU 
Unspiked 104 - - - - - - 
50 % 104 4 40 4.03+0.025 40.2+0.32 100.9+0.6 100.6+0.6 
100 % 104 8 80 8+0.03 80.5+0.64 99.9+0.3 100.7+0.8 
150 % 104 12 120 11.95+0.04 120.4+0.65 99.7+0.2 100.3+0.5 
(n=3 determinations) 
 
Table 8: Assay of the synthetic mixture by validated 1st order derivative spectroscopic method 
Drug Amount taken (µg/ml) Amount recovered (µg/ml) % Assay 
PAMA 8 7.99+0.6 100.0+0.6 




Spiked placebo with standard solution at 50, 100 and 150% level 
was analyzed for % recovery, which was found within 98 to 102, so 
the method was found to be accurate (table 7). 
Solvent stability 
As the λmax was stable over a period of 24 h, the solvent was found to 
be suitable and the drug was found to be stable. 
Assay 
When prepared synthetic mixture was analyzed by the developed 
and validated method, % assay was found to be 100.0+0.6 for PAMA 
and for100.1+0.7 IBU (table 8). 
CONCLUSION 
The 1st order derivative spectroscopic method was developed and 
validated as per ICH Q2 R1 guidelines and was successfully applied 
for determination of PAMA and IBU from its synthetic mixture. The 
present method was found to be economical in terms of cost and 
time. Commonly used excipient didn’t interfered in the estimation of 
PAMA and IBU so the method was found to be specific. Method was 
also found to be repeatable and precise.  
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